624 Results for "

allosteric inhibitor

" in MedChemExpress (MCE) Product Catalog:
Products (624)

624 Results for "allosteric inhibitor" in MCE Product Catalog:

1470
1470 Publications Verification
Art. -Nr.: HY-10219
CAS. Nr.: 53123-88-9
Reinheit:  99.94%
Synonyms: Sirolimus; AY-22989; NSC 226080
Rapamycin (Sirolimus; AY 22989) is a potent and specific blood-brain barrier-transmissible mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin is a molecular glue that binds FKBP12 and mTOR proteins together, thereby inhibiting mTOR kinase activity. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant .
loading...
    loading...
112
112 Cited Publications
Art. -Nr.: HY-10046
CAS. Nr.: 110078-46-1
Reinheit:  99.90%
Synonyms: AMD 3100; JM3100; SID791
Target:  

CXCR HIV

Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC50 of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC50 of 1-10 nM .
loading...
    loading...
76
76 Cited Publications
Art. -Nr.: HY-100388
CAS. Nr.: 1801747-42-1
Reinheit:  99.81%
Target:  

SHP2 Phosphatase

Forschungsgebiete:  

Cancer

SHP099 is an allosteric SHP2 inhibitor, with IC50s of 0.690, 1.241, 0.416, 1.968, 2.896 μM for SHP2, SHP2 D61Y, SHP2E69K, SHP2 A72V, SHP2 E76K. SHP099 inhibits cancer cell growth, such as MV4-11 and TF-1 cell (IC50: 0.32 and 1.73 μM). SHP099 inhibits RAS-ERK signaling and inhibits tumor growth .
loading...
    loading...
67
67 Cited Publications
Art. -Nr.: HY-10355
CAS. Nr.: 612847-09-3
Reinheit:  98.36%
Synonyms: AKTi-1/2
Target:  

Akt Apoptosis

Forschungsgebiete:  

Metabolic Disease Cancer

AKT inhibitor VIII (AKTi-1/2) is a cell-permeable quinoxaline compound that has been shown to potently, selectively, allosterically, and reversibly inhibit Akt1, Akt2, and Akt3 activity with IC50s of 58 nM, 210 nM, and 2119 nM, respectively.
loading...
    loading...
65
65 Cited Publications
Art. -Nr.: HY-15252
CAS. Nr.: 266359-93-7
Reinheit:  99.87%
Synonyms: Repertaxin L-lysine salt
Target:  

CXCR

Reparixin L-lysine salt is an allosteric inhibitor of chemokine receptor 1/2 (CXCR1/2) activation.
loading...
    loading...
65
65 Cited Publications
Art. -Nr.: HY-15251
CAS. Nr.: 266359-83-5
Reinheit:  99.99%
Synonyms: Repertaxin; DF 1681Y
Target:  

CXCR

Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors CXCR1 and CXCR2 activation with IC50s of 1 and 100 nM, respectively.
loading...
    loading...
64
64 Cited Publications
Art. -Nr.: HY-12683
CAS. Nr.: 314045-39-1
Reinheit:  98.07%
Target:  

Glutaminase

Forschungsgebiete:  

Cancer

BPTES is an allosteric and selective glutaminase inhibitor with an IC50 of 0.16 μM.
loading...
    loading...
53
53 Cited Publications
Art. -Nr.: HY-141520
CAS. Nr.: 2603528-97-6
Reinheit:  99.75%
Target:  

DNA/RNA Synthesis

Forschungsgebiete:  

Cancer

ART558 is a potent, selective and allosteric DNA polymerase theta (Polθ) inhibitor (IC50=7.9 nM). ART558 elicits BRCA-gene synthetic lethality and DNA damage. ART558 can be used for the research of cancer, such as breast cancer .
loading...
    loading...
50
50 Cited Publications
Art. -Nr.: HY-15310
CAS. Nr.: 70288-86-7
Reinheit:  98.28%
Synonyms: MK-933; CD-5024; K-237
Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. It is a positive allosteric effector of P2X4 and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibits bovine herpesvirus1 (BoHV-1) replication and inhibits BoHV-1 DNA polymerase nuclear import . Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19 .
loading...
    loading...
42
42 Cited Publications
Art. -Nr.: HY-119374
CAS. Nr.: 2270879-17-7
Reinheit:  99.72%
Target:  

SWI/SNF Complex

Forschungsgebiete:  

Cancer

BRM/BRG1 ATP Inhibitor-1 (compound 14) is an orally active allosteric dual brahma homolog (BRM)/SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily A member 2 (SMARCA2) and brahma related gene 1 (BRG1)/SMARCA4 ATPase activity inhibitor, both IC50s are below 0.005 µM. BRM/BRG1 ATP Inhibitor-1 has anticancer activity .
loading...
    loading...
41
41 Cited Publications
Art. -Nr.: HY-10299
CAS. Nr.: 1088965-37-0
Reinheit:  99.48%
Target:  

Kinesin Apoptosis

Forschungsgebiete:  

Cancer

GSK-923295 is a special, allosteric inhibitor of centromere-associated protein-E (CENP-E) kinesin motor ATPase activity, with Ki of 3.2±0.2 nM and 1.6± 0.1 nM for human and canine, respectively.
loading...
    loading...
38
38 Cited Publications
Art. -Nr.: HY-10518
CAS. Nr.: 547757-23-3
Reinheit:  99.90%
Target:  

IKK

Forschungsgebiete:  

Cancer

BMS-345541 hydrochloride is a selective inhibitor of the catalytic subunits of IKK (IKK-2 IC50=0.3 μM, IKK-1 IC50=4 μM). BMS-345541 binds at an allosteric site of IKK.
loading...
    loading...
38
38 Cited Publications
Art. -Nr.: HY-10519
CAS. Nr.: 445430-58-0
Reinheit:  99.86%
Target:  

IKK

Forschungsgebiete:  

Cancer

BMS-345541 is a selective inhibitor of the catalytic subunits of IKK (IKK-2 IC50=0.3 μM, IKK-1 IC50=4 μM). BMS-345541 binds at an allosteric site of IKK.
loading...
    loading...
36
36 Cited Publications
Art. -Nr.: HY-117287
CAS. Nr.: 1609392-27-9
Reinheit:  99.87%
Synonyms: BMS-986165
Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC50 of 0.2 nM and a Ki of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation . Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus .
loading...
    loading...
35
35 Cited Publications
Art. -Nr.: HY-12755
CAS. Nr.: 71203-35-5
Reinheit:  99.96%
Synonyms: CID-2950007
Target:  

Ras Apoptosis

Forschungsgebiete:  

Cancer

ML141 (CID-2950007) is a potent, allosteric, selective and reversible non-competitive inhibitor of Cdc42 GTPase. ML141 inhibits Cdc42 wild type and Cdc42 Q61L mutant with EC50s of 2.1 and 2.6 μM, respectively. ML141 shows low micromolar potency and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7). ML141 do not show cytotoxicity in multiple cell lines .
loading...
    loading...
20
20 Cited Publications
Art. -Nr.: HY-19719
CAS. Nr.: 1313881-70-7
Synonyms: ARQ-092
Target:  

Akt Parasite

Forschungsgebiete:  

Infection Cancer

Miransertib (ARQ-092) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research . Miransertib is effective against Leishmania .
loading...
    loading...
20
20 Cited Publications
Art. -Nr.: HY-19719A
CAS. Nr.: 1313883-00-9
Synonyms: ARQ-092 hydrochloride
Target:  

Akt Parasite

Forschungsgebiete:  

Infection Cancer

Miransertib hydrochloride (ARQ-092 hydrochloride) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib hydrochloride is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research . Miransertib hydrochloride is effective against Leishmania .
loading...
    loading...
19
19 Cited Publications
Art. -Nr.: HY-15713
CAS. Nr.: 1418013-75-8
Reinheit:  99.92%
Target:  

p97

Forschungsgebiete:  

Cancer

NMS-873 is a potent, selective allosteric VCP/p97 inhibitor with an IC50 value of 30 nM.
loading...
    loading...
16
16 Cited Publications
Art. -Nr.: HY-A0005
CAS. Nr.: 123318-82-1
Clofarabine, a nucleoside analogue for research of cancer, is a potent inhibitor of ribonucleotide reductase (IC50=65 nM) by binding to the allosteric site on the regulatory subunit .
loading...
    loading...
16
16 Cited Publications
Art. -Nr.: HY-104010
CAS. Nr.: 1492952-76-7
Reinheit:  99.61%
Synonyms: ABL001
Target:  

Bcr-Abl

Forschungsgebiete:  

Cancer

Asciminib (ABL001) is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM .
loading...
    loading...